Takeda announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in Primary Immunodeficiency Disease (PID) patients, ...

Immunodeficiency diseases have traditionally been defined as defects in the development and function of T and B cells, the primary effector cells of specific cellular and humoral immunity respectively ...

The FDA approved a supplemental biologics license application for Asceniv, expanding its use to younger patients with primary ...

Clinical data from a 16-patient pediatric study demonstrate the safety and efficacy of Asceniv in younger populations, ...

Please provide your email address to receive an email when new articles are posted on . Ocular manifestations appeared common among patients with primary immunodeficiency diseases, suggesting a need ...

The prevalence of primary immunodeficiency disease (PID) is approximately 1 in 10,000 children in the United States and 1 in 20,000 in Europe. It can be difficult to identify these children, and ...

Primary immunodeficiency occurs in people with immune systems that are either damaged or missing at birth. The condition appears in the form of “common infections“. This carries the risk of a medic ...

TORONTO, April 21, 2016 /CNW/ - Immunodeficiency Canada is honoured to have the generous support of the Jeffrey Modell Foundation in bringing the 10 Warning Signs to Canada. "Our first project, in the ...

PURPOSE: This study investigated the efficacy, toxicity, and pharmacokinetic interactions resulting from simultaneous combination chemotherapy and highly active antiretroviral therapy (HAART) for ...